Emergent BioSolutions (EBS) investor relations material

Executive summary

• Q1 2026 revenues were $156.1 million, exceeding guidance but down 30% year-over-year, driven by lower MCM and Commercial Product sales and the absence of prior-year one-time gains.

• Adjusted EBITDA was $36 million (23% margin), with net income at $6.8 million (4% margin), both down significantly from Q1 2025.

• The company advanced its multi-year transformation, focusing on growth, debt reduction, operational efficiency, and shareholder value through share repurchases and refinancing.

• Strategic partnerships and product launches included new NARCAN configurations, manufacturing collaborations, and expanded international presence.

• Debt refinancing in April 2026 improved strategic flexibility, lowered interest expenses, and extended maturities to 2031.

Financial highlights

• Q1 2026 revenue: $156.1 million, above guidance but down from $222 million in Q1 2025.

• Adjusted EBITDA: $36 million (23% margin); adjusted gross margin: 52% (down from 58% in Q1 2025).

• Net income: $6.8 million, down 90% year-over-year; adjusted net income: $11.9 million.

• Cash balance improved to $160.3 million; total liquidity at $260 million.

• Net debt reduced to $429 million from $551 million year-over-year; net leverage ratio improved to 2.4x.

Outlook and guidance

• Full-year 2026 revenue guidance maintained at $720–$760 million.

• Adjusted EBITDA guidance: $155–$175 million; adjusted net income: $45–$65 million; adjusted gross margin: 45–47%.

• Q2 2026 revenue expected between $170–$185 million.

• Management expects continued quarterly variability due to timing of production, deliveries, and government procurement.

• Liquidity and available credit are expected to fund operations for at least the next twelve months.